Last reviewed · How we verify
Placebo of Pioglitazone
Placebo of Pioglitazone is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Control arm in Phase 3 clinical trial of pioglitazone (indication dependent on parent trial).
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient. Used for Control arm in Phase 3 clinical trial of pioglitazone (indication dependent on parent trial).
At a glance
| Generic name | Placebo of Pioglitazone |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
As a placebo of pioglitazone, this formulation is designed to be indistinguishable from the active drug but contains no active ingredient. It serves as a control comparator in a Phase 3 randomized controlled trial to assess the efficacy and safety of pioglitazone relative to no pharmacological intervention. The actual pioglitazone mechanism (thiazolidinedione insulin sensitizer) is not present in this placebo formulation.
Approved indications
- Control arm in Phase 3 clinical trial of pioglitazone (indication dependent on parent trial)
Common side effects
- Placebo effect / nocebo effects (variable)
Key clinical trials
- Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude (PHASE4)
- SGLT2i, Pioglitazone, and Ketone Production in T2D (PHASE1)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Insulin Regulation of Lipolysis and Lipolysis Proteins (EARLY_PHASE1)
- Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer (PHASE2)
- Quantifying Hepatic Mitochondrial Fluxes in Humans (PHASE4)
- Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Pioglitazone CI brief — competitive landscape report
- Placebo of Pioglitazone updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Placebo of Pioglitazone
What is Placebo of Pioglitazone?
How does Placebo of Pioglitazone work?
What is Placebo of Pioglitazone used for?
Who makes Placebo of Pioglitazone?
What development phase is Placebo of Pioglitazone in?
What are the side effects of Placebo of Pioglitazone?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Control arm in Phase 3 clinical trial of pioglitazone (indication dependent on parent trial)
- Compare: Placebo of Pioglitazone vs similar drugs
- Pricing: Placebo of Pioglitazone cost, discount & access